Hengrui Pharma Reports Strong Growth and Strategic GLP-1 Pipeline Advancements in Q3 2026
Hengrui Pharma has reported robust financial results for the first nine months of 2026, highlighted by a 20.38% year-over-year increase in net profit to RMB6.92 billion. The company's transition toward innovation is evident as innovative drug sales rose by 17.05%, now accounting for nearly 65% of total drug sales. A significant driver of this growth was the non-oncology segment, which saw a massive 75.36% surge in revenue. The company's strategic focus on metabolic diseases is yielding results through its GLP-1 receptor agonist pipeline. Key regulatory milestones include the acceptance of NDAs for oral and dual-agonist GLP-1 products. Furthermore, Hengrui has strengthened its global footprint through high-value partnerships, including a major licensing deal with Novo Nordisk for HRS-1596 valued at up to US$2.6 billion, signaling strong international interest in its R&D capabilities.
Topics: Drug Approvals GLP-1 Pipeline Net Profit R&D Investment Revenue Growth
Read the full article at PR Newswire
Part of the story Hengrui Pharma Reports Strong Growth and Strategic GLP-1 Pipeline Advancements in Q3 2026 (2 articles)